UnitedHealth Surges Past $420 After Berkshire's Exit — Was Buffett's Team Too Early to Fold?

Berkshire's UnitedHealth Exit Looks Costly in Hindsight

When Berkshire Hathaway quietly stepped away from its UnitedHealth Group (NYSE: UNH) position earlier this year, few questioned the judgment of one of Wall Street's most celebrated investment operations. Now, with UNH shares recently touching $420, that decision is drawing fresh scrutiny — and raising questions about whether Warren Buffett and incoming CEO Greg Abel misjudged the timing of their departure.

Berkshire appears to have initiated its UnitedHealth stake in the second quarter of 2025, when shares averaged around $380, then exited the position in Q1 2026 when the stock had slumped to below $300. The subsequent rebound — fueled by improving insurance economics and a surprise government funding boost — means Berkshire likely absorbed a meaningful loss on the trade.

Why UnitedHealth Fell in the First Place

To appreciate the current recovery, it's important to understand what drove the stock's steep decline. Throughout 2024 and into 2025, U.S. health insurers faced an unexpected surge in medical costs that squeezed margins across the industry.

For health insurers, the medical care ratio — the share of premium revenue paid out in claims — is a critical profitability metric. The lower the figure, the more efficient the insurer. UnitedHealth's medical loss ratio deteriorated sharply, climbing from 85.5% in 2024 to 88.9% in 2025. The financial impact was severe: operating earnings plummeted from $32 billion to $19 billion in a single year, sending shares into a prolonged downtrend.

A Turning Point in 2026

The story in 2026 has shifted considerably. UnitedHealth has taken active steps to stabilize its cost structure, implementing premium price increases and exiting segments of the market that were generating losses. The results are beginning to show.

In Q2 2026, the company's medical care ratio improved to 86.7%, and management is guiding the full-year figure toward 88%, with ambitions to beat that target. Separately, an unexpected upward adjustment to Medicare Advantage reimbursement rates by the federal government gave the entire managed care sector an additional tailwind — one that analysts note was difficult to predict when Berkshire was making its exit.

Long-Term Growth Engine Remains Intact

Beyond the near-term cost recovery, UnitedHealth benefits from a structural tailwind that has supported the health insurance industry for decades. Healthcare spending in the United States has consistently outpaced broader economic growth, driven by demographic aging and increased emphasis on health outcomes.

For insurers positioned to capture a margin on total healthcare expenditure, this chronic inflation in medical costs translates into durable top-line growth. Data supports this dynamic: UnitedHealth's revenue has expanded by roughly 150% over the past decade, a trend that analysts suggest could persist as long as healthcare spending continues its long-term upward trajectory.

Valuation After the Rally

With shares recently trading near $420, UnitedHealth carries a market capitalization of approximately $380 billion. Against trailing net income of $14.9 billion, that implies a trailing price-to-earnings ratio of roughly 25.5x — not particularly inexpensive on the surface.

However, that trailing figure reflects a year of severely depressed earnings. At its prior profitability peak, the company generated net income well above $20 billion, and analysts project that UnitedHealth could reach $25 billion to $30 billion in annual net income within the next several years as the medical care ratio normalizes and revenues continue to grow. Against a $25 billion earnings scenario, the current market cap implies a forward P/E closer to 15x.

Management has also signaled a commitment to capital returns, guiding for at least $5 billion in shareholder distributions during the current fiscal year through share repurchases. A shrinking share count combined with earnings recovery could produce meaningful earnings-per-share growth over the medium term.

What Investors Are Watching

The central question for observers is whether UnitedHealth's medical care ratio can continue its descent back toward historical norms — or whether cost pressures reemerge and derail the recovery narrative. Progress on Medicare Advantage margins and the sustainability of the recent government reimbursement adjustments will also be closely monitored.

As for Berkshire, the episode serves as a reminder that even the most disciplined investment operations are not immune to market timing challenges. The UnitedHealth position may ultimately represent a rare stumble for a firm celebrated for its long-term conviction — though the full picture won't be clear until the dust on Berkshire's transition to Greg Abel's leadership fully settles.